ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
224.46
-2.28 (-1.01%)
Aug 14, 2026, 4:00 PM EDT - Market closed

ResMed Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
5,6535,1464,6854,2233,578
Revenue Growth
9.85%9.84%10.95%18.02%11.93%
Cost of Revenue
2,1702,0591,9971,8371,514
Gross Profit
3,4843,0872,6882,3862,064
Selling, General & Admin
1,108991.02917.14874737.51
Research & Development
378.29331.28307.53287.64253.58
Amortization of Goodwill & Intangibles
77.2577.3979.4872.4270.73
Operating Expenses
1,5641,4001,3041,2341,062
Operating Income
1,9201,6871,3841,1521,002
Interest Expense
--0.59-49.72-51.13-22.31
Interest & Investment Income
49.91----
Earnings From Equity Investments
6.963.64-1.85-7.27-8.49
Currency Exchange Gain (Loss)
--2.39-0.14-0.452.81
Other Non Operating Income (Expenses)
-9.151.830.66-1.510.39
EBT Excluding Unusual Items
1,9681,6901,3331,092974.55
Merger & Restructuring Charges
-33.23-2.03-64.23-20.13-1.86
Gain (Loss) on Sale of Investments
-15.01-10.3-4.059.92-12.2
Pretax Income
1,9191,6781,2651,102960.48
Income Tax Expense
396.12276.84243.85204.11181.05
Net Income
1,5231,4011,021897.56779.44
Net Income to Common
1,5231,4011,021897.56779.44
Net Income Growth
8.75%37.20%13.75%15.15%64.26%
Shares Outstanding (Basic)
146147147147146
Shares Outstanding (Diluted)
146147148147147
Shares Change
-0.87%-0.14%0.06%0.28%0.40%
EPS (Basic)
10.479.556.946.125.34
EPS (Diluted)
10.439.516.926.095.30
EPS Growth
9.67%37.43%13.63%14.91%63.58%

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Free Cash Flow
1,6501,6621,302573.63216.31
Free Cash Flow Per Share
11.2911.288.823.891.47
Dividend Per Share
2.4002.1201.9201.7601.680
Dividend Growth
13.21%10.42%9.09%4.76%5.66%
Gross Margin
61.62%59.99%57.38%56.50%57.68%
Operating Margin
33.96%32.79%29.54%27.28%28.01%
Profit Margin
26.95%27.22%21.79%21.25%21.78%
Free Cash Flow Margin
29.18%32.29%27.79%13.58%6.04%
EBITDA
2,1211,8601,5341,2921,126
EBITDA Margin
37.52%36.15%32.73%30.60%31.47%
D&A For EBITDA
201.34173149.42140.1124.06
EBIT
1,9201,6871,3841,1521,002
EBIT Margin
33.96%32.79%29.54%27.28%28.01%
Effective Tax Rate
20.64%16.50%19.28%18.53%18.85%
Revenue as Reported
-5,1464,6854,2233,578
SEC Filings: 10-K · 10-Q